Spatial architecture of the melanoma immune niche reveals CORO1A as a functional hub for T cell cytotoxicity and immunotherapy synergy.
Summary
Integrated single-cell and spatial transcriptomics defined immune and melanocyte spatial domains in melanoma and identified CORO1A as a key immune-niche regulator. CORO1A knockdown synergized with anti-PD-1 in vivo to suppress tumor growth, and inter-domain signaling axes (APP-CD74, FN1-CD44) were mapped.
Key Findings
- Two prognostically relevant spatial domains (Immune and Melanocyte regions) were defined in melanoma.
- Multi-omics convergence identified CORO1A as a key immune-niche regulator; its knockdown synergized with anti-PD-1 to suppress tumor growth in vivo.
- APP-CD74 and FN1-CD44 were mapped as key inter-domain communication axes impacting the immune niche.
Clinical Implications
While preclinical, the identification of CORO1A as a modulator of T-cell cytotoxicity suggests a tractable target for combination immunotherapy and a spatial framework for biomarker development and patient stratification.
Why It Matters
This work provides a spatially resolved mechanistic blueprint and nominates CORO1A as a combination target to potentiate ICB, addressing a major cause of therapeutic failure in melanoma.
Limitations
- Preclinical validation without randomized clinical trial data
- Sample size and cohort characteristics are not specified in the abstract, limiting generalizability
Future Directions
Prospective clinical studies to evaluate CORO1A as a biomarker/therapeutic target, and trials testing anti-PD-1 plus CORO1A-directed strategies with spatially informed patient selection.
Study Information
- Study Type
- Cohort
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical translational study integrating single-cell/spatial analyses with in vivo validation; no clinical intervention.
- Study Design
- OTHER